Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05956626
Other study ID # OCU410ST-101
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 25, 2023
Est. completion date October 28, 2025

Study information

Verified date March 2024
Source Ocugen
Contact Umair Qazi, MD, MPH
Phone +1 (202)-817-0787
Email umair.qazi@ocugen.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease. This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 42 subjects.


Description:

Name of Investigational Product: OCU410ST Name of Active Ingredient: Adeno-associated viral vector 5 human RORA (AAV5-hRORA) Title of Study: A Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease. Study Center(s): Approximately five clinical study centers in the US. Background: Stargardt disease is an eye disease that causes vision loss in children and young adults. It is an inherited disease caused by faulty genes that cause buildup of fat deposits in the eye. Currently, there is no approved treatment available for Stargardt disease. OCU410ST Product Information: OCU410ST is an Adeno-Associated Virus serotype 5 containing human RORA for the treatment of Stargardt disease. Dysregulation in lipid metabolism, oxidative stress, and anti-inflammatory mechanisms are critical for pathogenesis and progression of Stargardt disease. The role of hRORA in regulating these gene pathways strongly suggests OCU410ST could restore homeostasis in the eye and thereby serve as a therapeutic candidate for Stargardt disease. This study will be conducted in two phases. enrolling up to 42. Phase 1 is a multicenter, open-label, dose-ranging/dose escalation study with a 3+3 design enrolling up to 18 subjects Phase 2 is a randomized, dose-expansion cohort in which 24 subjects will be randomized in a 1:1:1 ratio in to either one of two treatment groups (adults and pediatric subjects) or to an untreated (adults and pediatric subjects) control group.


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date October 28, 2025
Est. primary completion date October 28, 2025
Accepts healthy volunteers No
Gender All
Age group 6 Years to 65 Years
Eligibility Inclusion Criteria: 1. Are aged 18-65. 2. Have clinical evidence of a macular lesion phenotypically consistent with Stargardt Disease 3. The study eye should have at least one well-demarcated area of atrophy with a minimum diameter of 300 microns, and total lesion size <= 18 mmE2 and a BCVA of 50 ETDRS letters or better 4. Have confirmed presence of two pathogenic mutations in the ABCA4 gene 5. Have detectable outer nuclear layer (ONL) in the macular region tomography (SD-OCT). 6. Have BCVA of 50 letters or less (using ETDRS chart) Key Inclusion Criteria for Pediatric Subjects: 1. Are aged 6-17. 2. Have clinical diagnosis of Stargardt Disease 3. The designated primary study eye must have at least one well-demarcated area of atrophy with a minimum diameter of 300 microns and a total lesion area <= 18 mmE2 and a BCVA of 35 ETDRS letters or better. 4. Have two (2) pathogenic mutations confirmed present, in the ABCA4 gene. Key Exclusion Criteria for Adult Subjects: 1. Have previous treatment with a gene therapy or cell therapy product. 2. Have any concurrent retroviral therapy that would inactivate the investigational product. 3. Have any contradictions for subretinal injection and the use of anesthesia. 4. Have genes that mimic Stargardt Disease like ELOVL4, or PROM1. Exclusion Criteria for Pediatric Subjects: 1. Have previous treatment with a gene therapy or cell therapy product. 2. Have any concurrent retroviral therapy that would inactivate the investigational product. 3. Have any intraocular surgery (including lens replacement surgery) within 6 months (prior to Screening), and any ophthalmic condition that may require surgery during the study period. 4. Have genes that mimic Stargardt Disease like ELOVL4, or PROM1.

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
OCU410ST
Subretinal Administration of OCU410ST

Locations

Country Name City State
United States Retina Consultants of Texas Bellaire Texas
United States Retina Foundation of the Southwest Dallas Texas
United States Duke Eye Center Durham North Carolina
United States Mississippi Retina Associates Jackson Mississippi
United States Bascom Palmer Eye Institute Miami Florida
United States Associated Retina Consultants Phoenix Arizona

Sponsors (1)

Lead Sponsor Collaborator
Ocugen

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in macular thickness on Spectra Domain Optical Coherence Tomography (SD-OCT) The change in the macular thickness will be Measured by spectral domain optical coherence tomography (SD-OCT) 12 months (Screening to 12 months post OCU410ST administration)
Other Change in Quality-of-life measure using NEI VFQ-25 (Adult subjects only) The National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ25) questionnaires will be administered to assess the impact of vision on quality of subject's life. 12 months (Screening to 12 months post OCU410ST administration)
Primary Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)) The primary endpoint is safety, determined by the number of ocular and non-ocular Study Drug-related adverse events (SDAE), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). 12 months (Screening to 12 months post OCU410ST administration)
Primary Ophthalmic Safety: Change From Baseline in BCVA (Best Corrected Visual Acuity) Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. 12 months (Screening to 12 months post OCU410ST administration)
Primary Ophthalmic Safety: Ophthalmoscope Measurements We will use Slit-lamp Biomicroscopy to visualize the anatomy of ocular structures before and after sub-retinal injections and follow-up visits. 12 months (Screening to 12 months post OCU410ST administration)
Primary Ophthalmic Safety: Change in the Intraocular Pressure (mmHg) Measured by applanation or rebound tonometry with confirmation with Goldmann tonometer if IOP is outside normal range (8-21mmHg). 12 months (Screening to 12 months post OCU410ST administration)
Primary Change Using Qualitative and quantitative assessments of autofluorescence pattern (FAF) Changes in the intensity of FAF will be evaluated from the baseline measurements, to assess the loss of retinal layers. 12 months (Screening to 12 months post OCU410ST administration)
Primary Ophthalmic Safety: Changes in Full Field ERG The International Society for Clinical Electrophysiology of Vision (ISCEV) guidelines will be followed for conducting ff-ERG (Full-field Electroretinography) 12 months (Screening to 12 months post OCU410ST administration)
Secondary Humoral and cellular immune response Blood samples will be collected for the assessment. The secondary safety endpoints include change from baseline in Humoral and cellular immune response in response to OCU410ST administration 12 months (Screening to 12 months post OCU410ST administration)
Secondary Shedding of Viral Vector Blood samples will be collected for the assessment to determine AAV vector shedding in systemic circulation after OCU410ST administration 12 months (Screening to 12 months post OCU410ST administration)
Secondary Change in laboratory parameters for Hematology Blood samples will be collected to determine any significant change in hematology parameters including hematocrit, hemoglobin, red and white blood cell count, and any other parameters deemed necessary by study investigator from baseline after OCU410ST administration. 12 months (Screening to 12 months post OCU410ST administration)
Secondary Change in laboratory parameters for Serum Chemistry Blood samples will be collected to determine any significant change in serum chemistry parameters including electrolytes, renal functions, liver functions, comprehensive metabolic panel and any other parameters deemed necessary by study investigator from baseline after OCU410ST administration. 12 months (Screening to 12 months post OCU410ST administration)
See also
  Status Clinical Trial Phase
Terminated NCT01676766 - Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease N/A
Enrolling by invitation NCT06048185 - Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Recruiting NCT04545736 - Oral Metformin for Treatment of ABCA4 Retinopathy Phase 1/Phase 2
Recruiting NCT05674058 - Function and Imaging Assessments for G1961E-associated Stargardt Disease
Recruiting NCT06435000 - An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Completed NCT04909398 - Pupil Dynamics and Color Vision for the Detection of Eye Diseases N/A
Completed NCT02255981 - Efficacy of Acupuncture in Macular Diseases N/A
Completed NCT05266014 - This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease Phase 1/Phase 2
Recruiting NCT06467344 - Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR) Phase 1/Phase 2
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Recruiting NCT06445322 - Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials
Completed NCT05417126 - Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease Phase 2
Completed NCT03772665 - Safety and Efficacy of Emixustat in Stargardt Disease Phase 3
Terminated NCT02875704 - Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
Completed NCT03033108 - Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease Phase 2
Recruiting NCT03011541 - Stem Cell Ophthalmology Treatment Study II N/A
Completed NCT02410122 - The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
Enrolling by invitation NCT04239625 - Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) Phase 2
Recruiting NCT02402660 - Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease Phase 2
Completed NCT01977846 - A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies